Firefighter Aged Garlic Extract Investigation With CoQ10 as a Treatment for Heart Disease (FAITH)
NCT ID: NCT00860847
Last Updated: 2015-03-12
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
65 participants
INTERVENTIONAL
2009-05-31
2010-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
According to the National Fire Protection Association (NFPA), 43.7% of all firefighters that died on the job experienced sudden cardiac death. The job also affords an incredible amount of stress. Cholesterol therapy has been well demonstrated to reduce coronary plaque progression. However is certainly not the only factor in evaluating for progression of coronary artery disease (CAD), and other factors must play a role. Garlic therapy has been shown to retard atherosclerosis independently.
2. Hypothesis and Specific Aims The hypothesis of this proposal is: In comparison to the placebo group, Aged Garlic Extract (AGE) therapy + Coenzyme Q10 (CoQ10) will be effective in slowing progression of coronary artery calcification (CAC) in firefighters with established atherosclerosis, independent of baseline blood pressure, statin use or other cardiovascular risk factors.
Specific Aims:
1. Compare the effects of cholesterol lowering effects in a firefighter population of patients under the influence of Aged Garlic Extract + CoQ10 or placebo.
2. Compare whether degree of change in atherosclerotic coronary artery plaque burden will change at a different rate under the influence of Aged Garlic Extract + CoQ10 compared to placebo treatment.
3. Compare whether Aged Garlic Extract + CoQ10 therapy induces changes in baseline values including biological and biochemical parameters, such as LDL cholesterol, homocysteine, C-reactive protein (CRP), and endothelial function.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Coenzyme Q10 in Relation to the Antioxidative Vitamins, Oxidative Stress and Inflammation in Coronary Artery Disease Patients During Statin Therapy
NCT01424761
Natural Heart Health Supplement Trial
NCT06671769
Plant Sterols on Cardiovascular Markers, Microbiota and Sterol Metabolism (Cardiofoodsterol)
NCT06481020
Effect of Aged Garlic Extract on Atherosclerosis
NCT01534910
Coenzyme Q10 in Relation of the Lipid Peroxidation, Antioxidant Enzyme Activities in Coronary Artery Disease Patients
NCT01163500
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Calcium scan with Agatston score \>20
* Age 35-84 years
* Subjects must provide written informed consent after the scope and nature of the investigation has been explained to them
* Subjects should be stable on their concomitant medications for at least 12 weeks prior to randomization
* Subjects who agree to refrain from supplemental garlic or significant dietary garlic
Exclusion Criteria
* A contraindication to Aged Garlic Extract therapy including: known hypersensitivity to drug.
* Any unstable medical, psychiatric or substance abuse disorder that in the opinion of the investigator or principal investigator is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study
* Weight in excess of 325 pounds
* Bleeding disorder
* History of myocardial infarction, stroke or life-threatening arrhythmia within the prior six months
* Resting hypotension (a resting systolic blood pressure of \<90 mm Hg) or hypertension (a resting blood pressure \> 170 mm Hg or a resting diastolic blood pressure of \>110 mm Hg)
* NYHA Class III or IV heart failure
* History of malignancy within the last 5 years (other than skin cancer) or evidence of active cancer which would require concomitant cancer chemotherapy
* Serum creatinine \> 1.4 mg/dl
* Triglycerides \> 400 at visit 1
* Diabetic subjects with HbA1c \> 12%
* Drug or alcohol abuse, or current intake of more than 14 standard drinks per week
* Concurrent enrollment in another placebo-controlled trial
* Presence of metal clips (i.e. bypass patients) or intracoronary stenting that preclude accurate measure of coronary calcification
* Partial ileal bypass or known gastrointestinal disease limiting drug absorption
* Current intake of garlic supplement or other prohibited drug (Appendix B)
* Current tobacco use
* Current use of anticoagulants (except for antiplatelet agents)
* Chronic renal failure
* Hematological or biochemical values at screening outside the reference ranges considered as clinically significant in the opinion of the investigator or PI
Outcome Measures Primary - Rate of change in total coronary calcium scores by CT The Agatston score was calculated by multiplying the lesion area (mm\^2) by a density factor. The density was measured in Hounsfield units, and score of 1 for 130-199 HU, 2 for 200-299 HU, 3 for 300-399 HU, and 4 for 400 HU and greater.
Secondary Change in blood values and endothelial function over 6 and 12 months:
1. Plasma lipids: total plasma cholesterol and triglycerides, LDL-Cholesterol, HDL-Cholesterol, and VLDL-Cholesterol determined by the precipitation method;
2. Endothelial markers and inflammation: C-reactive protein and Homocysteine, as well as GSH
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Aged Garlic Extract and Coenzyme Q10
AGE (1200 mg) and CoQ10 (120 mg)
This is a combination of aged garlic extract and co-enzyme Q10
Aged garlic extract and Coenzyme Q10
AGE (1200 mg) and CoQ10 (120 mg)
Placebo
placebo pills will be given
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aged garlic extract and Coenzyme Q10
AGE (1200 mg) and CoQ10 (120 mg)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 35-84 years
* Subjects must provide written informed consent after the scope and nature of the investigation has been explained to them
* Subjects should be stable on their concomitant medications for at least 12 weeks prior to randomization
* Subjects who agree to refrain from supplemental garlic or significant dietary garlic
Exclusion Criteria
* Any unstable medical, psychiatric or substance abuse disorder that in the opinion of the investigator or principal investigator is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study
* Weight in excess of 325 pounds
* Bleeding disorder
* History of myocardial infarction, stroke or life-threatening arrhythmia within the prior six months
* Resting hypotension (a resting systolic blood pressure of \<90 mm Hg) or hypertension (a resting blood pressure \> 170 mm Hg or a resting diastolic blood pressure of \>110 mm Hg)
* NYHA Class III or IV heart failure
* History of malignancy within the last 5 years (other than skin cancer) or evidence of active cancer which would require concomitant cancer chemotherapy
* Serum creatinine \> 1.4 mg/dl
* Triglycerides \> 400 at visit 1
* Diabetic subjects with HbA1c \> 12%
* Drug or alcohol abuse, or current intake of more than 14 standard drinks per week
* Concurrent enrollment in another placebo-controlled trial
* Presence of metal clips (i.e. bypass patients) or intracoronary stenting that preclude accurate measure of coronary calcification
* Partial ileal bypass or known gastrointestinal disease limiting drug absorption
* Current intake of garlic supplement or other prohibited drug (Appendix B)
* Current tobacco use
* Current use of anticoagulants (except for antiplatelet agents)
* Chronic renal failure
* Hematological or biochemical values at screening outside the reference ranges considered as clinically significant in the opinion of the investigator or PI
35 Years
84 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Matthew J. Budoff
Professor of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Matthew J Budoff, MD
Role: PRINCIPAL_INVESTIGATOR
University of California, Los Angeles
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Los Angeles Biomedical Research Institute
Torrance, California, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Libby P, Schoenbeck U, Mach F, Selwyn AP, Ganz P. Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization. Am J Med. 1998 Feb 23;104(2A):14S-18S. doi: 10.1016/s0002-9343(98)00041-2.
Lau BH, Li L, Yoon P. Thymic peptide protects vascular endothelial cells from hydrogen peroxide-induced oxidant injury. Life Sci. 1993;52(22):1787-96. doi: 10.1016/0024-3205(93)90468-i.
Weissberg PL, Bennett MR. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999 Jun 17;340(24):1928-9. No abstract available.
Raggi P, Callister TQ, Shaw LJ. Progression of coronary artery calcium and risk of first myocardial infarction in patients receiving cholesterol-lowering therapy. Arterioscler Thromb Vasc Biol. 2004 Jul;24(7):1272-7. doi: 10.1161/01.ATV.0000127024.40516.ef. Epub 2004 Apr 1.
Budoff MJ, Takasu J, Flores FR, Niihara Y, Lu B, Lau BH, Rosen RT, Amagase H. Inhibiting progression of coronary calcification using Aged Garlic Extract in patients receiving statin therapy: a preliminary study. Prev Med. 2004 Nov;39(5):985-91. doi: 10.1016/j.ypmed.2004.04.012.
Steiner M, Lin RS. Changes in platelet function and susceptibility of lipoproteins to oxidation associated with administration of aged garlic extract. J Cardiovasc Pharmacol. 1998 Jun;31(6):904-8. doi: 10.1097/00005344-199806000-00014.
BEUTLER E, DURON O, KELLY BM. Improved method for the determination of blood glutathione. J Lab Clin Med. 1963 May;61:882-8. No abstract available.
Mao S, Bakhsheshi H, Lu B, Liu SC, Oudiz RJ, Budoff MJ. Effect of electrocardiogram triggering on reproducibility of coronary artery calcium scoring. Radiology. 2001 Sep;220(3):707-11. doi: 10.1148/radiol.2203001129.
Ahmadi N, Hajsadeghi F, Gul K, Vane J, Usman N, Flores F, Nasir K, Hecht H, Naghavi M, Budoff M. Relations between digital thermal monitoring of vascular function, the Framingham risk score, and coronary artery calcium score. J Cardiovasc Comput Tomogr. 2008 Nov;2(6):382-8. doi: 10.1016/j.jcct.2008.09.001. Epub 2008 Sep 26.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Wakunaga of America Co., Ltd.
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.